LAMIVUDINE; RALTEGRAVIR POTASSIUM
| Brand name | DUTREBIS |
|---|---|
| Active ingredient | LAMIVUDINE; RALTEGRAVIR POTASSIUM |
| Strength | 150MG;EQ 300MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | February 2015 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 7754731*PED | September 2029 | — |
| 7754731 | March 2029 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.